Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=AVKUERGKIZMTKX-NJBDSQKTSA-N
InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ampicillin is a penicillin beta-lactam antibiotic. The following gram-negative and gram-positive bacteria have been shown in in vitro studies to be susceptible to ampicillin: Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli. Ampicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tract infections caused by susceptible strains of the designated organisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AMPICILLIN SODIUM Approved UseAmpicillin is indicated in the treatment of bacterial meningitis, septicemia, endocarditis, urinary tract, gastrointestinal, respiratory tracti nfections caused by susceptible strains of bacteria (Hemolytic and nonhemolytic streptococci, Streptococcus pneumoniae, Nonpenicillinase-producing staphylococci, Clostridium spp., B. anthracis, Listeria monocytogenes, most strains of enterococci, H. influenzae, N. gonorrhoeae, N. meningitidis, Proteus mirabilis, many strains of Salmonella, Shigella, and E. coli.) |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129.5 μg/mL |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 h |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: SULBACTAM |
AMPICILLIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20399996 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: PROBENECID |
AMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
72% |
AMPICILLIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (25%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
5 g 3 times / day multiple, intravenous Highest studied dose Dose: 5 g, 3 times / day Route: intravenous Route: multiple Dose: 5 g, 3 times / day Co-administed with:: Sulbactam(500 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
unhealthy, adult n = 9 Health Status: unhealthy Condition: Bacterial infections Age Group: adult Sex: M+F Population Size: 9 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.161 |
0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
Other AEs: Injection site pain... Other AEs: Injection site pain Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Other AEs: Injection site pain, Creatine phosphokinase increased... Other AEs: Injection site pain (grade 3-4, 100%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40Creatine phosphokinase increased (100%) |
2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Other AEs: Injection site pain, Rash... Other AEs: Injection site pain (1%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160Rash (1%) Diarrhea (5%) Fatigue (3%) Chills (1%) Headache (1%) AST increased (3%) Bilirubin increased (1%) Creatinine increased (1%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Other AEs: Chest pain, Flatulence... Other AEs: Chest pain (5%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53Flatulence (5%) Diarrhea (10%) Injection site pain (5%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Other AEs: Injection site pain, Phlebitis... Other AEs: Injection site pain (0.8%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57Phlebitis (5.3%) Chest pain (0.8%) Diarrhea (6.8%) Vomiting (0.8%) Retention of urine (0.8%) Rash (0.8%) Epistaxis (0.8%) Edema (0.8%) |
2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Other AEs: Thrombophlebitis, Nausea... Other AEs: Thrombophlebitis (6.7%) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155Nausea (6.7%) Diarrhea (6.7%) Rash (6.7%) Blood eosinophils increased (6.7%) AST increased (6.7%) ALT increased (13.3%) GGT increased (13.3%) Alkaline phosphatase increased (6.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin rash | 25% Disc. AE |
650 mg 3 times / day multiple, intravenous (mean) Studied dose Dose: 650 mg, 3 times / day Route: intravenous Route: multiple Dose: 650 mg, 3 times / day Co-administed with:: Sulbactam(300-350 mg; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
unhealthy, 11 to 18 months n = 4 Health Status: unhealthy Condition: acute pyelonephritis Age Group: 11 to 18 months Sex: M+F Population Size: 4 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.48 |
Injection site pain | 0.5 g 1 times / day single, intramuscular Recommended Dose: 0.5 g, 1 times / day Route: intramuscular Route: single Dose: 0.5 g, 1 times / day Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.36 |
|
Creatine phosphokinase increased | 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Injection site pain | grade 3-4, 100% | 1 g 1 times / day single, intramuscular Studied dose Dose: 1 g, 1 times / day Route: intramuscular Route: single Dose: 1 g, 1 times / day Co-administed with:: Sulbactam(0.5 g; single dose) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
healthy, adult n = 11 Health Status: healthy Age Group: adult Sex: M Population Size: 11 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.40 |
Bilirubin increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Chills | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Creatinine increased | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Headache | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Injection site pain | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Rash | 1% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
AST increased | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Fatigue | 3% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 5% | 2 g 1 times / day single, intramuscular Studied dose Dose: 2 g, 1 times / day Route: intramuscular Route: single Dose: 2 g, 1 times / day Co-administed with:: Sulbactam(1 g; single) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160probenecid(1 g; single) |
unhealthy, mean age 25.8 years n = 101 Health Status: unhealthy Condition: Acute uncomplicated gonorrhea Age Group: mean age 25.8 years Sex: M+F Population Size: 101 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.160 |
Diarrhea | 10% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Flatulence | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Injection site pain | 5% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
unhealthy, mean age 27.1 years n = 21 Health Status: unhealthy Condition: Endomyometritis Age Group: mean age 27.1 years Sex: F Population Size: 21 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.53 |
Chest pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Edema | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Epistaxis | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Injection site pain | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Rash | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Retention of urine | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Vomiting | 0.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Phlebitis | 5.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
Diarrhea | 6.8% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
unhealthy, mean age 27.4 years n = 131 Health Status: unhealthy Condition: Peritonitis associated with appendicitis Age Group: mean age 27.4 years Sex: M+F Population Size: 131 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.57 |
ALT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
GGT increased | 13.3% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
AST increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Alkaline phosphatase increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Blood eosinophils increased | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Diarrhea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Nausea | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Rash | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Thrombophlebitis | 6.7% | 2 g 3 times / day multiple, intravenous Studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Co-administed with:: Sulbactam(1 g; 3/day) Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
unhealthy, mean age 60.1 years n = 15 Health Status: unhealthy Condition: Pneumonia Age Group: mean age 60.1 years Sex: M+F Population Size: 15 Sources: Page: nda/pre96/050608Orig1s000rev.pdf - p.155 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 2.0 |
yes [Inhibition 1000 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Acute interstitial nephritis following ampicillin hypersensitivity. | 1975 Jan 18 |
|
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection. | 2001 |
|
Superantigen antagonist peptides. | 2001 |
|
Antibiotic susceptibility, serum response and surface properties of Klebsiella species. | 2001 |
|
[Achromobacter xylosoxidans bacteremia in a patient with community-acquired pneumonia]. | 2001 |
|
Effect of granulocyte-macrophage colony-stimulating factor on treatment of acute osteomyelitis. An experimental investigation in rats. | 2001 |
|
Enterobacter spp. infections complicating the course of HIV disease. | 2001 Apr |
|
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait. | 2001 Apr |
|
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia. | 2001 Apr |
|
Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center. | 2001 Apr |
|
Infant botulism: case reports and review. | 2001 Apr |
|
The isolation and characterization of Campylobacter jejuni subsp. jejuni from domestic geese (Anser anser). | 2001 Apr |
|
Antibiotic resistance among Listeria, including Listeria monocytogenes, in retail foods. | 2001 Apr |
|
[Beta-lactamase negative ampicillin-resistant Haemophilus influenzae(BLNAR)]. | 2001 Apr |
|
[Beta-lactam and macrolide resistance in Streptococcus pneumoniae]. | 2001 Apr |
|
[Vancomycin-resistant enterococci(VRE)]. | 2001 Apr |
|
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2001 Apr 1 |
|
Fulminant pneumonia due to Aeromonas hydrophila in a man with chronic renal failure and liver cirrhosis. | 2001 Feb |
|
Enterococcus faecalis resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil. | 2001 Feb |
|
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate. | 2001 Feb |
|
Vibrio parahaemolyticus associated with cholera-like diarrhea among patients in North Jakarta, Indonesia. | 2001 Feb |
|
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. | 2001 Feb |
|
[Streptococcus gallolyticus infections in racing pigeons, a literature review]. | 2001 Feb 1 |
|
Clostridium difficile--Associated diarrhea: A review. | 2001 Feb 26 |
|
Illegal abortions in Addis Ababa, Ethiopia. | 2001 Jan |
|
Synthesis and properties of dextran-linked ampicillin. | 2001 Jan |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. | 2001 Jan |
|
Carboxydobrachium pacificum gen. nov., sp. nov., a new anaerobic, thermophilic, CO-utilizing marine bacterium from Okinawa Trough. | 2001 Jan |
|
Adhesion to a polymeric biomaterial affects the antibiotic resistance of Staphylococcus epidermidis. | 2001 Jan |
|
A suicide-substrate mechanism for hydrolysis of beta-lactams by an anti-idiotypic catalytic antibody. | 2001 Jan 26 |
|
Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens. | 2001 Jan-Feb |
|
[Immunocorrecting and protective effect of proteolytic enzymes on antibody formation in mice in staphylococcal infection and antibiotic treatment]. | 2001 Jan-Feb |
|
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk. | 2001 Jan-Feb |
|
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. | 2001 Mar |
|
Antibiotic-resistant bacteria in pediatric chronic sinusitis. | 2001 Mar |
|
Neonatal sepsis and mortality in a regional hospital in Trinidad: aetiology and risk factors. | 2001 Mar |
|
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test. | 2001 Mar |
|
Longitudinal surveillance of antibiotic use in the hospital. | 2001 Mar |
|
Improved agar diffusion method for detecting residual antimicrobial agents. | 2001 Mar |
|
Antimicrobial resistance in salmonellae from humans, food and animals in Spain in 1998. | 2001 Mar |
|
Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
Ureidopenicillins and risk of Clostridium difficile infection. | 2001 May |
|
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. | 2001 May |
|
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. | 2001 May 15 |
|
Treatment of foodborne listeriosis. | 2001 May 15 |
|
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. | 2001 Spring |
|
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods. | 2001 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/ampicillin.html
Ampicillin Dosage and Administration
This insert is for a Pharmacy Bulk Package and is intended for preparing IV admixtures only. Dosage recommendations for intramuscular or direct intravenous injection are for informational purposes only.
Infections of the respiratory tract and soft tissues.
Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
Infections of the gastrointestinal and genitourinary tracts (including those caused by Neisseria gonorrhoeae in females).
Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.
Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6- to 8- hour intervals.
In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.
Urethritis in males due to N. gonorrhoeae.
Adults – Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.
In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.
The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral Ampicillin may be made when appropriate.
Bacterial Meningitis
Adults and children – 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.
Septicemia
Adults and children – 150 to 200 mg/kg/day. Start with intravenous administration for at least three days and continue with the intramuscular route every 3 to 4 hours.
Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14195635
Ampicillin was tested in vitro for antibacterial activity against 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Taking the group of 673 isolates tested as a whole, 448 (67 %) were inhibited by ampicillin at a concentration of 5 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:14 GMT 2023
by
admin
on
Fri Dec 15 15:11:14 GMT 2023
|
Record UNII |
7C782967RD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ51RC20
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 522.90
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
LIVERTOX |
NBK547894
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-ATC |
J01CR01
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
WHO-VATC |
QJ51CA51
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ51CA01
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 520.90E
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ01CR01
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ51CR01
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000175497
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-ATC |
J01CA51
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 520.90B
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
WHO-VATC |
QG51AG04
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ01CA01
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-VATC |
QJ01CA51
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 520.90F
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
WHO-ATC |
S01AA19
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
IARC | Ampicillin | ||
|
WHO-VATC |
QS01AA19
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 556.40
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
WHO-VATC |
QG51AG05
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.1
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 520.90
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
CFR |
21 CFR 520.90D
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
NDF-RT |
N0000011281
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
WHO-ATC |
J01CA01
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
||
|
WHO-VATC |
QG51AG07
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
||
|
CFR |
21 CFR 520.90C
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05487MIG
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
PRIMARY | |||
|
C239
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
AMPICILLIN
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
AMPICILLIN
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antibiotic. Storage: Ampicillin should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Ampicillin should state whether the substance is in the anhydrous form or is the trihydrate. Additional information: Even in the absence of light, Ampicillin is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Ampicillin contains not less than 95.0% and not more than 102.0% of C16H19N3O4S, calculated with reference to the anhydrous substance. | ||
|
Ampicillin
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
31209
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
221058
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
DB00415
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
198
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
SUB11710MIG
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
PRIMARY | |||
|
DTXSID4022602
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
1033000
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
D000667
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
7C782967RD
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
Ampicillin and Sulbactam
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
733
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
ALTERNATIVE | |||
|
6249
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
100000092323
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
200-709-7
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
7C782967RD
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
28971
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
PRIMARY | |||
|
528986
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
m1853
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL174
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
3009
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
1339
Created by
admin on Fri Dec 15 15:11:15 GMT 2023 , Edited by admin on Fri Dec 15 15:11:15 GMT 2023
|
PRIMARY | |||
|
69-53-4
Created by
admin on Fri Dec 15 15:11:14 GMT 2023 , Edited by admin on Fri Dec 15 15:11:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
Ampicillin is anhydrous or contains three molecules of water of hydration
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
ENZYME->SUBSTRATE |
Leads to resistance to the antibiotic.
|
||
|
PARENT -> DEGRADENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
For the trihydrate use about 0.1 g of the substance; the water content is not less than 120 mg/g and not more than 150 mg/g.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
PARENT -> IMPURITY | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
For the anhydrous form use about 0.8 g of the substance; the water content is not more than 15 mg/g.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||